阿斯利康选择上海作为其第五个全球战略中心，集研发、商业和生产运营于一体。 AstraZeneca selects Shanghai as its fifth global strategic hub, integrating R&D, commercial, and production operations.
英国制药巨头阿斯利康将上海作为其第五个全球战略中心，集研发、商业和生产运营于一体。 AstraZeneca, a UK pharma giant, has named Shanghai as its fifth global strategic hub, integrating R&D, commercial, and production operations. 该公司看到了将本地创新全球化并促进上海和长三角地区中国临床研究数据的全球认可的重大机遇。 The company sees significant opportunities to globalize local innovations and promote global recognition of Chinese clinical research data in Shanghai and the Yangtze River Delta region. 阿斯利康进入中国30多年，致力于开拓广阔的中国市场。 AstraZeneca, present in China for over 30 years, is dedicated to exploring the vast Chinese market.